Search research articles
Contact Us
Filters
Showing results (391-400 of 487) with videos related to
Page
of 49
Sort By:
Investigational New Drugs
|
October 27, 2021
Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study
Kyaw Zin Thein, Sarina A Piha-Paul, Apostolia Tsimberidou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 2, 2023
Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma
Vivek Subbiah, Sant P Chawla, Anthony P Conley, et al.
Journal for Immunotherapy of Cancer
|
September 20, 2019
Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma
Mouhammed Amir Habra, Bettzy Stephen, Matthew Campbell, et al.
JCO Precision Oncology
|
February 9, 2022
Circulating <i>BRAF</i> V600E Cell-Free DNA as a Biomarker in the Management of Anaplastic Thyroid Carcinoma
Priyanka C Iyer, Gilbert J Cote, Tao Hai, et al.
NPJ Precision Oncology
|
July 31, 2024
Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations
Sarina A Piha-Paul, Chieh Tseng, Cheuk Hong Leung, et al.
Oncotarget
|
April 21, 2017
Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas
Roman Groisberg, David S Hong, Vijaykumar Holla, et al.
Oncotarget
|
November 21, 2017
Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience
Jennifer B Goldstein, Chad Tang, Kenneth R Hess, et al.
BMJ Open
|
May 2, 2025
A phase I, open-label, multicentre, first-in-human study to evaluate safety, pharmacokinetics and efficacy of AMG 404, a PD-1 inhibitor, in patients with advanced solid tumours
Timothy Price, Iwona Lugowska, Sant P Chawla, et al.
Investigational New Drugs
|
October 28, 2017
Radiomics to predict immunotherapy-induced pneumonitis: proof of concept
Rivka R Colen, Takeo Fujii, Mehmet Asim Bilen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 14, 2025
Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials
Jia Liu, Max Farrow, Lesley Seymour, et al.
Page
of 49
Search research articles
Search
Showing results (391-400 of 487) with videos related to
Sort By:
Page
of 49
Investigational New Drugs
|
October 27, 2021
Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study
Kyaw Zin Thein, Sarina A Piha-Paul, Apostolia Tsimberidou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 2, 2023
Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma
Vivek Subbiah, Sant P Chawla, Anthony P Conley, et al.
Journal for Immunotherapy of Cancer
|
September 20, 2019
Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma
Mouhammed Amir Habra, Bettzy Stephen, Matthew Campbell, et al.
JCO Precision Oncology
|
February 9, 2022
Circulating <i>BRAF</i> V600E Cell-Free DNA as a Biomarker in the Management of Anaplastic Thyroid Carcinoma
Priyanka C Iyer, Gilbert J Cote, Tao Hai, et al.
NPJ Precision Oncology
|
July 31, 2024
Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations
Sarina A Piha-Paul, Chieh Tseng, Cheuk Hong Leung, et al.
Oncotarget
|
April 21, 2017
Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas
Roman Groisberg, David S Hong, Vijaykumar Holla, et al.
Oncotarget
|
November 21, 2017
Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience
Jennifer B Goldstein, Chad Tang, Kenneth R Hess, et al.
BMJ Open
|
May 2, 2025
A phase I, open-label, multicentre, first-in-human study to evaluate safety, pharmacokinetics and efficacy of AMG 404, a PD-1 inhibitor, in patients with advanced solid tumours
Timothy Price, Iwona Lugowska, Sant P Chawla, et al.
Investigational New Drugs
|
October 28, 2017
Radiomics to predict immunotherapy-induced pneumonitis: proof of concept
Rivka R Colen, Takeo Fujii, Mehmet Asim Bilen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 14, 2025
Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials
Jia Liu, Max Farrow, Lesley Seymour, et al.
Page
of 49